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A B S T R A C T
Deagglomeration of cohesive particles in combination with coarse carrier is a key require-
ment for inhaled formulations.The aim of the project was to propose amathematical approach
to understand aerosolization behaviour of micronized particles alone and in formulation
with carriers. Salbutamol sulphate and salmeterol xinafoate were blended separately with
fine lactose (ratio 1:4) and fine and coarse lactose (1:4:63.5). Laser diffraction was em-
ployed to characterize the powder median particle size.The deagglomeration of micronized
materials followed an asymptotic monoexponential relationship.When the coarse lactose
was added, the relationship fitted a bi-exponential equation showing an easily and a poorly
dispersed fraction. Using model hydrophobic and hydrophilic APIs, this study has demon-
strated the utility of an analytical approach that can parameterize deagglomeration behaviour
of carrier-free and carrier-based inhalation formulations. The analytical approach pro-
vides the ability to systematically study the effect of material, formulation and processing
factors on deagglomeration behaviour.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Shenyang Phar-
maceutical University. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Micronized particles for inhalation with size between 1 and 5 μm
form agglomerates due to the dominance of interparticulate
forces. Several dry powder formulations have been marketed
without the presence of carrier particles [1,2]. The absence of
the coarse particle affects the performance of formulations that
contain extensive agglomeration [1,2]. Budesonide (Bud), for
example, is more cohesive than salbutamol sulphate (SS),
showing bigger agglomerates under the SEM (scanning elec-
tron microscope) [3]. It has been suggested [3–5] that FP
(fluticasone propionate), like SX (salmeterol xinafoate) and Bud,
shows greater agglomeration forces than SS. However, the for-
mation of agglomerates of micronizedAPIs leads to an increased
entrainment of the drug particles but poor blend flowability.To
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address the manufacturing challenge of cohesive agglomer-
ates, drug particles are often blended with coarse lactose carrier
to improve flowability, uniformity of dosing and aerosoliza-
tion. Many drug particles remain agglomerated in such carrier
blends. During aerosolization, particles must be removed from
the carrier particles and agglomerates must be disrupted in the
airflow [6,7].
Micronized material (e.g. FP (fluticasone propionate)) shows
highly-cohesive behaviour, forming big agglomerates, espe-
cially when carrier is added (median agglomerate size
40.15 ± 6.02 at 90 L min−1) [8].The authors [8] mixed coarse and
fine lactose with the most cohesive batch of FP and the for-
mulation generated a lower fine particle fraction than when
the coarse carrier was not used.The authors [8] suggested that
it was due to the presence of very large agglomerates of FP in
the mixtures. Different types of blending, such as high- or low-
shear blending, lead to the re-arrangement of the API on the
surface of the carrier. The mechanism of re-distribution of the
API on the carrier particles differs from drug to drug (includ-
ing batch-to-batch variability of the same drug), and depends
on how great the cohesive force between agglomerates is [9].
Although all micronized particles are cohesive, when coarse
carrier such as lactose is added to the formulation, the mi-
cronized material starts to redistribute on the lactose surface
exhibiting very different behaviour [8,10,11]. When energy is
applied to the formulation (such as inhalation strength of the
patient), the cohesive forces between agglomerates would be
overcome and they would be released together with the fine
material for lung deposition.
Salbutamol sulphate (SS), which has been widely investi-
gated [10,12,13], presents a rectangular or a plate-like shape
when analysed under the SEM [13]. Other studies [10,12] sug-
gested that SS exhibits an adhesively balanced behaviour when
added to coarse lactose and redistributes evenly on the lactose
surface, with lower adhesive energy to the carrier with respect
to other particles [10].This is probably due to the relative balance
of cohesive and adhesive interparticulate forces in binary (and
ternary) formulations with carriers. SS showed a lower cohe-
sive energy compared to Bud, with SX also reported to exhibit
a balance in favour of cohesion when added to lactose [10,14,15].
The interaction between lactose and drug particles has to be
strong enough to prevent segregation. However, upon aero-
solization, the drug must be easily detached to allow lung
deposition.
The design of an inhaler and the inhalation strength of the
patient affect the geometries and forces available for powder
entrainment and drug dispersion. The forces of interaction
within the powder formulation additionally play a role in the
aerosolization. Studies have demonstrated that the strong ad-
hesion between API and coarse carrier decreased the drug
dispersion [11,16]. Enhancement of the dispersion process (e.g.
aerosol fraction of fine particles) and modification of inter-
particulate forces within the powder formulation by the
presence of ternary agent have been suggested [17,18]. Adi et al.
[11] showed that adding fine lactose improved the dispersion
process of SX from the coarse carrier, because the interac-
tion between the fine lactose and the SX produced mixed
agglomerates. It may be the decreased drug/carrier adhesion
energy or the easier break-up of mixed agglomerates with low
carrier adhesion that enhances dispersion efficiency.
It has been suggested that the addition of fine lactose would
increase the respirable fraction [19], whilst the presence of
coarse lactose improves the flowability of the formulation.
However, Behara et al. [20] showed that the presence of coarse
carrier is not necessary. The aerosolization was improved by
doubling the ratio of fine lactose to SS (from 1:4 to 1:8). They
suggested that increasing the concentration of fine lactose
reduced the agglomerate strength between SS and fine lactose
[20]. Studying the impact of drug type or the properties of co-
formulated excipients on deagglomeration with a focus on blend
segregation into drug or drug-excipient agglomerates repre-
sents a ‘blend structure’ treatment of deagglomeration. However,
focusing blend segregation (which can be assessed through
studying the effects of content uniformity on dispersion during
aerosolization [21]) ignores the fundamental causes of blend
structure (or restructuring).These include the effects of the order
of material addition in blending [22], of electrostatic charge [23]
and tribo-electrification during blending, the blending energy
and duration of blending [21,24] that are employed, and of
course inhaler device design itself and tribo-electrification [25]
behaviour of the aerosol that is being dispersed from the device.
However, it remains of merit to consider the resultant inter-
particulate forces between formulation components, the balance
of the agglomerative and deagglomerative forces applied during
blending with respect to eventual deagglomeration perfor-
mance of the blend. The adhesion forces between drug and
carrier consist mainly of inter-particulate forces such as van
der Waals forces, electrostatic charges, and capillary interac-
tions and influence aerosol dispersion from dry powder inhalers
(DPIs) [26].
Inverse gas chromatography, centrifugation and atomic force
microscopy have been used to characterize adhesion forces
between particles [27,28]. However, such techniques do not
quantify the cohesion of an actual powder bed as it only mea-
sures the interaction between one drug or excipient particle
and the probe of the AFM.
Other studies investigated the interaction between indi-
vidual particles using atomic force microscopy (AFM) [27,28]
and suggested CAB (cohesive-adhesive balanced) approach. CAB
approach calculated the ratio between API agglomerates and
adhesion of API to the carrier. It suggests that CAB ratio < 1 the
drug is more adhesive to the carrier than to itself, whilst a
CAB > 1 indicates that more drug agglomerates can be found
in the formulation, leading to a variable content uniformity [5].
However, the technique does not quantify the adhesion force
of the powder bed as it only measures the interaction between
one particle or excipient and the probe of the AFM. Other tech-
niques have been proposed to study the interaction between
particles. For instance, inverse phase gas chromatography [29]
showed potential to understand the interaction between carrier
and API, where the formulation is placed inside a packed
column and a gas (e.g. helium) is passed through it. The API
with higher affinity to the carrier would elute later than the
one with less affinity. This is due to the higher surface energy
between API particles and carrier. Studying the retention of a
range of probes with different polarity and chemistry, the co-
hesion strength can be calculated [29]. Other techniques to study
the different behaviour of blends under applied forces are
powder rheometry (where flow properties are studied by study-
ing the movement of an impeller through blends under a
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specified force, such as torque) [30] and centrifugation of mi-
cronized material [31].
Laser diffraction techniques have been used for dry and
liquid dispersion systems to study powder deagglomeration [32].
Airflow and pressure drop titration experiments have been per-
formed [4,32] to assess the change in particle size when a fine
powder bed is subjected to an increasing pressure drop and
empirical models have been proposed for micronized par-
ticles with or without the common carrier coarse lactose
[4,32,33].
When only micronized APIs are present in the formulation
alone or in presence of fine lactose, studies have suggested that
the liberation of fine particles <6 μm shows a sigmoidal trend
with increasing airflow rate and a three-parameter sigmoidal
equation has been used [32].The latter relationship suggested
that parameters such asmaximum extent of deagglomeration
or flow rate required to achieve 50% deagglomeration could be
used to predict powder deagglomeration.However, the problem
occurs when the coarse lactose is added to the formulation.
Higher flow rates are required to deaggregate themixture fully
than if the lactose carrier were not present. Therefore, more
energy is required to fully aerosolizemicronizedAPIs away from
the surface of the carrier.An equation similar to the Langmuir
adsorption isotherm was proposed with the name of Powder
Aerosol Deaggregation Equation [33]. However, the authors
suggested the use of a cascade impactor together with a dry
powder inhaler for the experiments that would affect the
deagglomeration of the particles. The use of cascade impac-
tion is not a rapidmethod to guide formulation choice in early
phases of product development. Previous studies have indi-
cated the benefits of a rapidmethodology using laser diffraction
to guide formulation of DPIs. However, the models proposed
to explain the deagglomeration process did not show any pa-
rameter with a physical meaning.The aim of this study was to
develop a data modelling approach to characterize and pa-
rameterize powder deagglomeration response to airflow for
cohesivemicronizedparticles aloneor in formulationwith coarse
andfine carrier.Thiswould behelpful to predict deagglomeration
mechanisms of novel formulations or following different phar-
maceutical processing.
2. Materials and methods
2.1. Materials
Micronized salbutamol sulphate (SS, batch number B027798)
was obtained from GlaxoSmithKline Research and Develop-
ment (Ware, UK). Salmeterol xinafoate (SX) was purchased from
Vamsi Labs Ltd (Solapur, India). Lactose monohydrate, Span 80
and cyclohexane were purchased from FisherScientific (Lough-
borough, UK). Fine lactose (LH300) was donated from Friesland
Foods (The Netherlands). Adhesive carbon tabs and alu-
minium pin stubs were purchased fromAgar Scientific Ltd (UK).
2.2. Blend preparation
Lactose monohydrate (Fisher Scientific, UK) was sieved to sepa-
rate the 63–90 μm particle fractions using a mechanical sieve
shaker (model – AS 200 digit, Retsch, Germany) with the 90 μm
sieve and the 63 μm sieve. It was operated for 5 min at 100 am-
plitudes.The fraction of lactose between the sieves was collected
to prepare the blends. A total of 3 g of blends were prepared.
The drugs were blended separately with either fine lactose (FL)
in ratio 1:4, coarse lactose (CL) in ratio 1:67.5 or combination
of both in ratio 1:4:63.5.The drug was sandwiched with coarse
lactose (CL) in equal volumes. When the FL was used, it was
first blended with the drug and the pre-mixture sandwiched
with coarse lactose. Glass vials were used for the blending and
vortexed (Vortex Genie 2, model G – 560E, Scientific Indus-
tries LTD, New York) for 2 min. The blending was carried out
in a Turbula mixer (Turbula 2583, type +2C, Glen Mills, Clifton)
for 40 min.
2.3. Particle size analysis
Salbutamol sulphate (SS), fine lactose (FL), salmeterol xinafoate
(SX) and coarse lactose (CL) were tested for the homogeneity
of the particle size using the laser diffraction technique. The
Sympatec Rodos module (Inhaler Helos/KF, Sympatec Limited,
Bury, UK) with Aspiros feeder was used.The speed of the feeder
was set at 25 mm/s.The pressure drop was set between 0.1 and
5.0 Bar in order to titrate the dispersion pressure.The PSD (par-
ticle size distribution) was collected every 0.1 Bar when tested
from 0.1 to 1.0 Bar and every 1.0 Bar when tested from 1.0 to
5.0 Bar. The duration of the measurements was 5 s. The
optimum concentration of the powder to be detected was in
the range of 1.0 and 1.1%. The technique was used to detect
the particle size of the blend as a dry dispersion.
A liquid laser diffraction technique using a Malvern
Mastersizer X (Malvern Instruments Ltd, UK) was also used to
determine the ‘true’ fully dispersed particle size. The blends
were suspended in 0.5% (w/v) Span 80 in cyclohexane (for SX
blends, SX, FL, CL) and 1% (w/v) Span 80 (for SS blends and SS).
Malvern Mastersizer X (Malvern Instruments Ltd, UK) was used
with 100 mm focal length lenses (0.5–180 μm) and MS7 mag-
netically stirred cell. Prior to measurement, the solvents were
saturated with the appropriate particles and sonicated for
30 min followed by overnight stirring. For the measurements,
approximately 1 mg of powder was added to 2 mL filtered dis-
persant (0.2 μm cellulose acetate syringe filter, Sartorius Stedim
Biotech., UK) and sonicated (Sonicleaner, DAWE, Ultrasonics Ltd,
USA) for 1 min for SS, FL and CL and 5 min for SX. The stir-
ring was set at 3 min for all the powders with sweeps of 2500
for SX and 3500 for the other powders. A background reading
was taken and the suspension was added to the sample cell
until the obscuration was 10–30%. Following equilibration (60 s
for SX and 30 s for the others), ten individual measurements
were taken for n = 3 samples. From the instruments, Dv10, Dv50,
and Dv90 (corresponding to the cumulative percentage par-
ticle undersize values for 10%, 50% and 90% of the particles
by volume), and the % volume <5 μm were used for analysis.
2.4. Particle morphology assessment
Powder samples were transferred to adhesive carbon tabs,
mounted onto aluminium pin stubs (Agar Scientific Ltd,
England). To assess blend interactions, scanning electron mi-
croscopy (SEM, Jeol Carry Scope JCM 5700,Welwyn Garden City,
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UK) was performed. Samples were sputter coated with gold
under argon for 4 min to achieve a thickness of approx. 30 mm
using an Emitec SC 7620 coater (QuorumTechnologies Limited,
West Sussex, England). To view the particle morphology, the
SEM was operated at 15 kV in low vacuummode and a working
distance of 13 mm.
2.5. Equation of deagglomeration and mathematical
model
The % relative deagglomeration for micronized particles was
calculated using the model proposed by Behara et al. [32] in
Equation (1).
%
%
%
RD
volume m dry dispersion
volume m liquid dispersion
=
< ( )
< (
5
5
μ
μ ) ∗100 (1)
where % RD is the relative deagglomeration.
2.6. Statistical analysis
Statistical analysis was performed in Minitab (version 15) using
one-way ANOVA and post-hoc Tukey’s test (multiple compari-
sons) or Student’s two-tailed t test for pair-wise comparisons,
both at 95% confidence intervals. Non-linear regression analy-
sis of the powder dispersion data was performed using
OriginPro (ver. 8) and MatLab software (ver. R2013a).
3. Results and discussion
The aim of the current study was to propose a model in order
to understand the deagglomeration mechanisms of micron-
ized material for inhalation in combination with fine and/or
coarse carrier. The design of an inhaler and the inhalation
strength of the patients allow the dispersion of inhaled formu-
lations and lung deposition. However, upon aerosolization, the
API (active pharmaceutical ingredient) might deaggregate in a
different manner depending on the presence or absence of a
coarse carrier or also on its distribution on the lactose surface
prior to release from the inhaler [4]. Coarse lactose is well known
to be used to improve aerosolization and flowability of micron-
ized drug [12,34]. However, a strong adhesion of the API to the
carrier would decrease the drug dispersion [11,16]. Therefore,
ternary agents (or fine lactose) are usually added to the formu-
lation to compete with the drug on the active sites of the carrier.
Saturating high adhesive-energy surface sites, the drug can be
detached easily from the carrier during aerosolization [34,35].
Behara et al. [20] showed that the presence of coarse carrier was
not necessary to improve aerosolization.The addition of lactose
fines in increasing concentration successfully reduced the co-
hesive strength of drug agglomerates, leading to better
aerosolization. Moreover, Islam et al. [36] indicated that SX dis-
persion increased as the amount of FL increased. Fine lactose
and cohesive micronized particles created agglomerates [20].
Using laser diffraction techniques, the effect of the addi-
tion of either fine lactose or coarse lactose to theAPI was shown
[36]. On the other hand, adding coarse carrier to the mixture
shifted the distribution to a larger size range [36]. Studying the
deagglomeration process of the dispersed powder at differ-
ent flow rates has featured widely in the literature.A few studies
have investigated the deagglomeration trend of either the
powder bed [4] or the aerosol emitted from a Rotahaler [32].
These studies proposed a quick methodology to assess
deagglomeration of the formulation upon increasing flow rate
or pressure drop. Laser diffraction analyses such as Sympatec
and Malvern instrument [4,32] were used. However, the studies
seem to focus on the fine particles, rather than on the formu-
lation with coarse carrier.
3.1. Laser diffraction analysis
In order to understand the deagglomerationmechanism, blends
with either SX or SS were manufactured in-house with differ-
ent grades of lactose and their aerosolization was studied using
laser diffraction techniques.All formulations were regarded uni-
formity (%CV < 10%); however, content uniformity was poorer
for blends with fine lactose (Table 1). For the purpose of the
study and to understand the different deagglomeration mecha-
nism of SX and SS, the former was considered cohesively-
balanced when added to the lactose, due to its tendency to
create agglomerates on the carrier surface [15]. On the other
hand, SS was considered due to its adhesively balanced
behaviour when added to lactose as previously described [12].
The concentration of the SS and SX was 1.48% w/w and they
were blended with either FL (1:4), coarse lactose (1:67.5) or both
(1:4:63.5).
When the APIs were dispersed using the Sympatec/RODOS
for pressure drop titration, both SX and FL showed a bi-modal
Table 1 – Particle size distribution for pure material and blends of salbutamol sulphate (SS) and salmeterol xinafoate (SX)
with lactose using liquid dispersion laser diffraction (mean ± SD, n = 3) and content uniformity for the inhalation blends
(coefficient of variance (%CV) of n = 6 determinations). FL = fine lactose, CL = coarse lactose.
Materials Ratio Dv10
(μm)
Dv50
(μm)
Dv90
(μm)
Volume
% <5 μm
Content uniformity
(%CV)
SX n/a 0.90 ± 0.01 3.01 ± 0.05 7.40 ± 0.33 76.15 ± 1.22 n/a
SS n/a 1.38 ± 0.03 3.63 ± 0.05 10.02 ± 0.40 66.15 ± 0.56 n/a
LH300 n/a 1.51 ± 0.01 3.40 ± 0.07 6.76 ± 0.13 75.71 ± 1.25 n/a
SS:CL 1:67.5 4.96 ± 3.11 53.42 ± 8.75 92.76 ± 2.83 13.36 ± 6.87 1.31
SS:FL:CL 1:4:63.5 4.60 ± 1.27 57.36 ± 4.07 95.24 ± 1.68 11.45 ± 2.74 1.35
SS:FL 1:4 1.38 ± 0.04 3.60 ± 0.16 9.03 ± 1.07 68.76 ± 2.69 5.94
SX:CL 1:67.5 4.79 ± 3.65 56.05 ± 3.98 89.32 ± 11.57 12.50 ± 3.98 0.32
SX:FL:CL 1:4:63.5 2.11 ± 0.43 43.35 ± 12.68 84.82 ± 8.61 22.87 ± 7.76 5.32
SX:FL 1:4 1.23 ± 0.03 3.15 ± 0.06 6.73 ± 0.23 77.89 ± 0.82 3.17
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PSD at 0.5 Bar (Fig. 1A and 1B). The same trend was seen also
for SS that exhibited a similar behaviour at 1 Bar (Fig. 1C), sug-
gesting a greater energy is required for the deagglomeration
mechanism to occur for SS compared to SX and FL. However
SS, SX and FL showed a bell-shaped distribution at higher pres-
sure drops as confirmed in previous studies [22,37]. When FL
was added to the APIs, a more consistent distribution was seen
for both drugs when the pressure was increased. However, SS–
FL deagglomeration at low pressure (0.5 Bar) did not occur
completely (shoulder in the large particle size range in Fig. 2A).
The same trend was seen by Jaffari et al. [4] with SX, and by
Behara et al. for SS:FL [32]. However, the bi-modal distribu-
tion was not present for SS:FL at 1 Bar unlike for SS alone,
probably due to the addition of the FL leading to disruption
of SS agglomerates and enhanced deagglomeration [20].
When the formulations containing either CL or FL:CL were
analysed, the lactose carrier showed a distribution in the
60–90 μm range (Fig. 3A). However, in blends also containing
FL, a shoulder was seen in themicronized region due to a higher
amount of fine particles present in the mixture (Fig. 3B). The
formulations showed a bi-modal distribution due to the pres-
ence of easily-dispersible agglomerates (small shoulder in the
respirable range) and a poorly-dispersible fraction of drug still
attached to the carrier (large shoulder) [4,35].
Liquid dispersion laser diffraction was used to determine
the fully dispersed particle size of the API and blends. The
results confirmed the dry dispersion trend of the blends as the
Dv50 of the blends with the carrier were shifted to higher values
than when the drugs were blended with fine lactose only
(Table 1). On the other hand, the micronized API possessed a
PSD within the micron size range (Table 1).
3.2. Empirical model
The DV50 was plotted for all micronized material and formu-
lations (Fig. 4A) and the descending part of the graph prior the
plateau shows different deagglomeration behaviour between
particles and formulations (e.g. SS vs. SX and FL in Fig. 4A).The
difference, especially at low pressure drops, suggests variabil-
ity in agglomerate size and strength as suggested from the
density distributions of size in Fig. 1. The % relative
deagglomeration (equation 1) was also plotted (Fig. 4B) and SX
reached the maximum deagglomeration earlier than SS, which
on the other hand, did not reach a constant particle size at the
highest pressure (Fig. 4B).When FL was added to both APIs, an
increase in the degree of deagglomeration was seen at 2 Bar,
which then decreased at 3 Bar (Fig. 4B). This was probably due
to the instability of the formulation at high pressure drops.
The % relative deagglomeration for micronized particles and
micronized formulations showed a mono-exponential trend
when a pressure drop was applied to the agglomerates. The
trend could be explained by Equation (2) which is a modifica-
tion of the Johnson–Mehl–Avrami–Kolmogorov (JMAK) equation
[38]:
y m e x x
n
= −( )−( )1 0 (2)
Due to the high variability in the replicate measurements,
an artificial error was added when normalizing the data.
The deagglomeration mechanism depends on the distri-
bution of the APIs either alone or in combination with FL in
formulation. The slope of the curve (Table 2) is the maximum
gradient and represents how readily the deagglomeration
process occurs before the drug reaches the plateau size
(deagglomeration sensitivity). The plateau size represents the
maximum deagglomeration (“m” parameter in Table 2 defines
the positive asymptote of the curve) which varies with the type
of particle (Table 2). This was in accordance with Jaffari et al.
[4], where formulations with fine particles reached a
monoexponential plateau when the pressure drop was in-
creased. SS showed the lowest maximum gradient (indicating
a deagglomeration process that is resistant to increased airflow)
when pressure is applied compared to the other micronized
materials (Table 2, P < 0.05). The difference, especially at low
pressure drops, suggests variability in agglomerate size (i.e. x0
in Equation 2) and strength between agglomerates [5,14]. In
order to compare the drugs and blends, the critical pressure
point (CPP), the pressure point corresponding to reaching 95%
of the maximum deagglomeration, was calculated. SS started
to reach the plateau at 1.25 ± 0.19 Bar, at a much greater pres-
sure than SX or FL (Table 2, P < 0.05). However, when FL was
added to SS, the CCP95 was reached at lower pressure than when
SS was analysed alone (0.84 ± 0.08 Bar, P < 0.05) and the greater
maximum gradient was seen for FL than SS (Table 2, P < 0.05).
The maximum gradient is a vector of the derivative of the
function. This indicates the rate of ascent of the curve,
therefore, the rate of the degree of deagglomeration. If a small
tangent is drawn in a selected point (in this case x0;y0),
then the maximum gradient refers to the slope of the
tangent.
The enhanced degree of deagglomeration seen for SS due
to addition of FL could be explained by creation of mixed SS-
FL agglomerates of lower cohesive strength than SS-
agglomerates [20,32]. Therefore, the cohesion forces between
API (or API–FL) agglomerates are reduced. SX:FL had a poor
deagglomeration compared to FL or SX, suggesting that the ad-
dition of FL to very cohesive agglomerates does not improve
the deagglomeration mechanism [39]. In accordance with this
theory, Adi et al. [15] showed that increasing the shear pres-
sure to formulations of SX containing FL with different size
range (3.0 and 7.9 μm) was required especially for formula-
tion containing FL 3.0 μm.This might be a result of segregation
in the formulation. The parameters ‘x0’ and ‘n’ are inter-
dependent. The parameter ‘x0’ has a similar meaning to the
parameter proposed by Behara et al. [32]. The authors used a
Rotahaler with Spraytec to study the deagglomeration behaviour
of either SS or FL. They suggested that the parameter was the
dispersion energy required to overcome internal interaction of
the agglomerates. In the current work we suggested that ‘x0’
could be seen as an inflection point and therefore the pres-
sure at which the deagglomeration attempts to reach the
maximum point. In accordance with Behara et al. [32], the
blends with fine particles and FL alone showed similar ‘x0’
values (Table 2, P > 0.05) with the exception of SS. The param-
eter ‘n’ is the trend of the first part curve between 0.1 and x0
Bar. SS:FL exhibited the highest deagglomeration exponent
whilst SX:FL showed the smallest. This indicates a different
deagglomeration mechanism when the fine lactose over-
comes SS–SS and SX–SX interactive forces. Moreover, the blend
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Fig. 1 – Density distribution of size of (A) salmeterol xinafoate, (B) fine lactose LH300 and (C) salbutamol sulphate between
0.5 and 5 Bar.
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structure plays a role. Adding the fine lactose would modify
the adhesive strength between particles and enhance the de-
tachment of the API (Table 2, maximum gradient was greater
for SS:FL than SX:FL).
When CL was added to the formulation, the plateau was
not reached for the blends containing CL. Instead, the formu-
lations showed a bi-exponential trend (Fig. 5) highlighting an
easily dispersed fraction and a second poorly dispersible frac-
tion of respirable particles. This response is described by
Equation (3).
y A e H x x A ex x w x x= −( ) + −( ) −( ) −( )−( ) −( )1 100 11 2 (3)
‘A’ represents the amplitude of the easily dispersed frac-
tion (i.e., extent of deagglomeration),whereas 100 − ‘A’ represents
the deagglomeration extent of the poorly dispersed fraction;
‘xw’ is the pressure when the poorly dispersible fraction starts
to deagglomerate; ‘H’ is the Heaviside-function (1 if x > xw, 0
if x < xw); x1 and x2 are pressure points when the de-
agglomeration response is at maximum for the easily and poorly
dispersed fractions, respectively.
The bimodal distribution of certain blends was attributed
to the presence of coarse carrier in the formulation that, when
pressure was applied led to a release of easily dispersible ag-
glomerates (fine particles) and a poorly dispersible fraction of
large cohesive agglomerates. The trend of the latter seemed
to be the same for all the formulations. However, differences
were observed in the initial exponential region of the
deagglomeration curves of the blends. SS:CL seemed to have
the steepest curve compared to the other API:CL blends. As ex-
pected, API:FL:CL blends showed a steeper slope in the first
fraction than API:CL blends (Fig. 5).They showed also a greater
% of deagglomeration expressed by the parameter “A” in equa-
tion (3). SX:FL:CL for example showed 170.97 ± 12.74 bar−1 and
SX:CL presented 71.64 ± 7.42 bar−1. At high pressures there was
an increase in the release of fine particles. The presence of a
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Fig. 2 – Density distribution of size of (A) salbutamol sulphate:fine lactose blends and (B) salmeterol xinafoate:fine lactose
blend between 0.5 and 5 Bar.
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ternary agent would help the detachment of the micronized
API from the surface of the carrier, resulting in greater respi-
rable fraction for the patient than when the formulation was
composed of CL only [39] (higher ‘A’ parameter, Table 3). The
greatest ‘A’-value was observed for SS:FL:CL (Table 3). Jones et al.
[39] also confirmed improved detachment when alternative
ternary agents were added to binary formulations by showing
an increased mode in the respirable fraction for Bud ternary
erythriol-lactose formulations.
Equation (3) shows the Heaviside function (H) which is
usually used in engineering to represent a parameter that
changes abruptly at specified values of time t. In the current
model the step function (or Heaviside function) was applied
to the bi-exponential trend. A small plateau can be observed
in Fig. 5, between 1.0 and 2.0 Bar, between the end of the
deagglomeration of the easily dispersed fraction and the be-
ginning of the deagglomeration of the poorly dispersed fraction
[40]. ‘H’ was applied to the deagglomeration mechanism of the
blends with coarse carrier, where the “H” parameter of the func-
tion was 1 if x > xw, with xw being the pressure when the poorly
dispersed fraction starts to deagglomerate (the delayed unit),
or 0 if x < xw. All the formulations with the exception of SX:CL
showed the plateau between the easily and the poorly dis-
persed fraction, with SS:CL showing the highest pressure value.
This suggested that this particular formulation required the
highest pressure to deagglomerate. The addition of FL led to
a greater deagglomeration as the pressure (xw) decreased by
1 unit. Furthermore, the corresponding % deagglomeration to
xw was the highest between all the formulations (Table 3).
3.3. Particle morphology
Microscopy was employed to examine blend structure. Unlike
what some studies have suggested [4,10], SS did not exhibit a
plate-like shape (Fig. 6A), whereas both APIs created elon-
gated agglomerates without clear differentiation in their shape
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Fig. 3 – Density distribution of size of (A) salbutamol sulphate:coarse lactose blend and (B) salmeterol xinafoate:fine
lactose:coarse lactose blend between 0.5 and 5 Bar.
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(Fig. 6). Moreover, when added to coarse lactose, no differ-
ence in the API distribution was seen on the surface of the
carrier (Fig. 7). This particle behaviour is different to what was
proposed previously in the literature. Begat et al. suggested that
SS distributes evenly on the surface of the carrier [10]. SX created
agglomerates due to the fact that SX–lactose blends are domi-
nated by SX cohesive interactions [11]. However, this was not
shown in the current work. Nevertheless, different re-
distribution behaviour of the two different APIs was clearly seen
when FL was added to the API–CL mixtures (Fig. 8). The addi-
tion of FL to SX:CL (Fig. 8B) led to more agglomerates of FL–
SX being heterogeneously distributed on the lactose surface,
presenting larger agglomerates on the extremities of the carrier
compared to when FL was absent in the formulation.This was
probably due to the weak adhesion of FL to the carrier surface,
and therefore, its tendency to agglomerate with SX [35]. This
suggests that SX–FL have stronger adhesion than FL:FL.Adi et al.
[35] showed that when the concentration of fines (i.e. SX and
FL) was increased, a better detachment of agglomerates from
the lactose was observable because of saturation of the active
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0
0
10
20
30
40
50
60
70
80
90
100
110
120
R
el
at
iv
e 
%
 d
ea
gg
lo
m
er
at
io
n
Pressure drop (bar)
SS
SX
FL
SS:FL
SX:FL
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5
0
10
20
30
40
50
60
70
80
90
100
110
D
v 5
0 (
μm
)
Pressure drop (Bar)
SS
SX
FL
SS:FL
SX:FL
A B
Fig. 4 – Graph of (A) median particle size and (B) deagglomeration behaviour as a function of pressure drop for micronized
salmeterol xinafoate (SX, red), salbutamol sulphate (SS, black), fine lactose (FL, blue), salbutamol sulphate:fine lactose
(SS:FL, green) and salmeterol xinafoate:fine lactose (SX:FL, pink) (mean ± SD, n = 3).
Table 2 – Mono-exponential deagglomeration parameters for salbutamol sulphate (SS), salmeterol xinafoate (SX), fine
lactose (FL) and SS–FL or SX–FL blends.
Materials m
(%)
x0
(bar)
n Maximum gradient
(bar−1)
CPP95
(bar)
R2
FL 101.99 ± 3.00 0.49 ± 0.02 2.65 ± 0.35 289.05 ± 32.08 0.74 ± 0.05 0.98274
SX 101.18 ± 2.19 0.53 ± 0.03 2.03 ± 0.27 194.27 ± 9.67 0.90 ± 0.05 0.98606
SS 99.89 ± 2.61 0.69 ± 0.04 1.53 ± 0.17 108.88 ± 5.06 1.25 ± 0.19 0.98587
SS:FL 103.40 ± 5.40 0.61 ± 0.04 2.71 ± 0.71 230.20 ± 34.34 0.84 ± 0.08 0.93928
SX:FL 99.40 ± 1.60 0.43 ± 0.01 1.68 ± 0.12 207.35 ± 6.1 0.82 ± 0.04 0.99360
m = positive asymptote.
x0 = pressure value in the x axis which takes a value of n ≥ 0.
n = deagglomeration exponent.
Maximum gradient = slope of the curve.
CPP95 = critical primary pressure where the degree of deagglomeration has reached the 95% of its final value.
R2 = value of the best fitted line.
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Fig. 5 – Bi-exponential distribution of the % relative
deagglomeration for salbutamol sulphate and salmeterol
xinafoate blended with coarse lactose (SS:CL black, SX:CL
pink) and with fine lactose (SS:FL:CL blue, SX:FL:CL grey)
(mean ± SD, n = 3).
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sites on the carrier. This led to a better interaction between
SX and FL causing agglomeration and surface detachment.The
authors proposed that this was due to the fact that adhesion
force between SX and CL was lower than SX–SX and SX–FL [35].
This potentially shows the strong cohesive behaviour of SX par-
ticles that is likely to create agglomerates.
The same tendency to create agglomerates was seen for FL–
SS, and “free” agglomerates of FL:SS were visible in the space
between carrier particles (Fig. 8B).When energy is applied, these
agglomerates would be dispersedmore easily compared to those
adhered to the surface of the carrier (e.g. in SX:FL:CL), leading
to the higher % deagglomeration for the SS:FL:CL compared
to SX:FL:CL (“A” parameter, Table 3). In fact, the maximum gra-
dient value for SS:FL (Table 2) was greater than SX:FL, suggesting
that the aerosolization of SS was enhanced in presence of the
FL. However, the adhesive strength predicted (Table 3) of the
CL–SS interactions in the agglomerates would require high
pressure to achieve full deagglomeration (xw = 3.0 ± 0.3 for SS:CL
in Table 3).
4. Conclusion
The study revealed a rapid technique to characterize the
deagglomeration behaviour of micronized particles during for-
mulation development. The micronized particles showed
different deagglomeration processes to each other suggest-
ing variability in agglomerate size and strength between
agglomerates. The empirical parameterization was descrip-
tive of agglomerate and powder structure and deagglomeration
mechanisms. The micronized particles (including one model
hydrophobic API and one model hydrophilic API) showed dif-
ferent deagglomeration processes to each other suggesting
Table 3 – Parameters from a bi-exponential equation for salbutamol sulphate (SS) blends (FL = fine lactose, CL = coarse
lactose) and salmeterol xinafoate (SX) blends.
Blends A
(%)
x1
(bar)
x2
(bar)
xw;yw
(bar;%)
R2
SS:CL 37.6 ± 0.7 0.5 ± 0.0 11.2 ± 2.8 3.0 ± 0.3; 37.4 ± 0.8 0.81143
SS:FL:CL 61.4 ± 2.6 0.6 ± 0.1 3.7 ± 1.0 2.0 ± 0.3; 59.8 ± 6.4 0.91714
SX:CL 17.8 ± 2.8 0.3 ± 0.1 14.0 ± 1.0 0;0 0.88214
SX:FL:CL 48.7 ± 1.8 0.3 ± 0.0 5.6 ± 1.4 1.9 ± 0.4; 48.6 ± 1.6 0.91714
A B
Fig. 6 – Scanning electron microscopy images for (A) salbutamol sulphate and (B) salmeterol xinafoate.
A B
Fig. 7 – Scanning electron microscopy images for (A) salbutamol sulphate:coarse lactose and (B) salmeterol xinafoate:coarse
lactose.
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variability in agglomerate size and strength between agglom-
erates. Co-formulating with a coarse carrier and fine lactose
did modify the deagglomeration process suggesting that two
different types of fractions of dispersed particles can be iden-
tified when increasing dispersing airflow.Moreover, SEM studies
suggested a greater number of free agglomerates for SS:FL:CL
than SX:FL:CL, leading to higher dispersion of the micronized
material. Inhaler devices play a major role in the aerosoliza-
tion of the formulation. Previous powder deagglomeration
models have been proposed with specific devices (such as the
Rotahaler) and additional work is required to expand our un-
derstanding of the implications of adding lactose (or other
excipients) for the aerosolization of blends when used in other
device platforms. However, we believe that the outcomes of the
current study (albeit using a limited range of API and excipi-
ent materials and low shear blending) provide for good starting
point for future rapid screening experiments into the effects
of multiple material, formulation, blend and processing prop-
erties and provide functionally-relevant parameters of
deagglomeration performance for DPI blends.
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